𝔖 Bobbio Scriptorium

✦ LIBER ✦

Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel

✍ Scribed by Giorgio Bolis; Giovanna Scarfone; Saverio Tateo; Giorgia Mangili; Antonella Villa; Fabio Parazzini

Book ID: 112248299
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 36 KB
Volume: 80
Category: Article
ISSN: 0090-8258
DOI: 10.1006/gyno.2000.5995

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-766 Phase II study of topotecan (T) an

P-766 Phase II study of topotecan (T) and paclitaxel (P) as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED-SCLC)

✍ Hainsworth, J.; Palmer, M.; Granick, J.; Boston, B.; Bonomi, P.; Althouse, D.; D 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB